GlaxoSmithKline (H Q)
“GlaxoSmithKline (H Q)” is a location label, not a registered company
“GlaxoSmithKline (H Q)” reads as a label for the GSK group’s US headquarters office in Philadelphia, Pennsylvania. It is not the name of a legal person. On 22 October 2026 we searched the Pennsylvania Department of State’s open dataset of active business registrations (data.pa.gov, dataset xvd7-5r2c, rows updated 6 October 2026) for every registration containing “GLAXO”, “SMITHKLINE” or “GSK”. No registration is filed under “GlaxoSmithKline (H Q)” or any similar headquarters name. The same query, run in the same session for “Comcast Cable”, returned Comcast’s registrations, so the search works. A label has no registration number, legal form, formation date or register status, so the stored “Active” status has no register behind it.
GSK’s US website and GSK plc’s 2025 Annual Report on Form 20-F give the group’s US investor-relations and contact address as 2929 Walnut Street, Suite 1700, Philadelphia, PA 19104. Neither document names the legal entity that occupies that office.
Registered GSK legal persons in Pennsylvania (context, not this record’s identity)
The Pennsylvania dataset lists several GSK group registrations. GlaxoSmithKline LLC is registered in Pennsylvania as a Foreign Limited Liability Company, filing number 0003913524, with a registration date of 27 October 2009. GLEIF records it as a Delaware limited liability company (Delaware file number 4746253, LEI 549300Y2PZWSSLJYI255), with status ACTIVE and an entity creation date of 27 October 2009. A Schedule 13D that GSK filed with the SEC in December 2010 describes GlaxoSmithKline LLC as formerly known as SmithKline Beecham Corporation. The Pennsylvania dataset also still carries a “Smithkline Beecham Corporation” foreign business corporation record (0003913516) with the same 27 October 2009 date. The Department of State says the dataset over-counts active businesses because of statutory limits on removing ones that no longer operate. Nothing on this record ties it to one of these entities rather than another, so this page does not attribute their identifiers to it.
What the GSK group does (group facts)
GSK plc, registered in England and Wales under company number 03888792, is a biopharmaceutical group. It develops and sells specialty medicines, vaccines and general medicines. For the year ended 31 December 2025 it reported total turnover of £32,667 million, up 4% at actual exchange rates and 7% at constant exchange rates, and total operating profit of £7,932 million. The group employed 66,841 people at the end of 2025, of whom 11,807 were in the US. These are consolidated group figures, not figures for any US entity. GSK plc’s ordinary shares are listed on the London Stock Exchange, and its American Depositary Shares, each representing two ordinary shares, trade on the New York Stock Exchange under the symbol GSK.
Sources
- Pennsylvania Department of State, Registered Businesses in PA (data.pa.gov dataset xvd7-5r2c): https://data.pa.gov/resource/xvd7-5r2c.json, rows updated 6 October 2026, retrieved 22 October 2026
- GLEIF LEI record 549300Y2PZWSSLJYI255: https://api.gleif.org/api/v1/lei-records/549300Y2PZWSSLJYI255, last updated 23 July 2026, retrieved 22 October 2026
- GSK plc, Schedule 13D on Anacor Pharmaceuticals, filed 10 December 2010: https://www.sec.gov/Archives/edgar/data/1411158/000095012310112757/c09546sc13d.htm, retrieved 22 October 2026
- GSK plc, 2025 Annual Report on Form 20-F, filed 6 March 2026: https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm, retrieved 22 October 2026
- GSK, “GSK delivers strong 2025 performance”, 4 February 2026: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/, retrieved 22 October 2026
- GSK US, Contact us: https://us.gsk.com/en-us/contact-us/, retrieved 22 October 2026
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of GlaxoSmithKline (H Q)
“GlaxoSmithKline (H Q)” is a location label for the GSK group’s US headquarters office in Philadelphia, not a company. A label has no share capital, members or shareholders, and no Pennsylvania registration exists under this name (Pennsylvania Department of State open data, searched 22 October 2026, with a same-session positive control). This page therefore lists no shareholders for the record.
As context only: GSK plc’s 2025 Annual Report on Form 20-F lists GlaxoSmithKline LLC, the Delaware limited liability company registered in Pennsylvania as a foreign LLC, among the group’s wholly owned subsidiaries. The holding is shown as 100% of the LLC interests, held indirectly by GSK plc as at 31 December 2025. The report does not name the immediate member.
GSK plc is listed in London and New York. Its 2025 Annual Report on Form 20-F records two notified interests in its voting rights, unchanged between 31 December 2025 and 25 February 2026. BlackRock, Inc. holds 231,975,400 voting rights (5.69%), indirectly, through ordinary shares, ADS and contracts for difference. Dodge & Cox holds 253,464,108 voting rights (5.04%), indirectly, through ordinary shares and ADS. Each percentage was calculated at the date it was notified to GSK. These are disclosures by asset managers, not control. Only major holdings above the UK notification threshold are published.
Data availability
Availability: not applicable to the label. For the group parent, only major shareholders are published. Pennsylvania’s open registration data contains no ownership fields. Other notifications made to GSK plc after 25 February 2026 may have changed these figures.
Sources
- GSK plc, 2025 Annual Report on Form 20-F (major shareholders; full list of subsidiaries), filed 6 March 2026: https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm, retrieved 22 October 2026
- Pennsylvania Department of State, Registered Businesses in PA (data.pa.gov dataset xvd7-5r2c): https://data.pa.gov/resource/xvd7-5r2c.json, rows updated 6 October 2026, retrieved 22 October 2026
Officers
Directors and officers of GlaxoSmithKline (H Q)
“GlaxoSmithKline (H Q)” is a location label for the GSK group’s US headquarters office in Philadelphia, not a company. It has no directors, managers, governors or officers of its own. No Pennsylvania registration exists under this name, so the Department of State’s open data holds no officer entries for it (searched 22 October 2026, with a same-session positive control).
As context only: the Pennsylvania dataset lists two entries in the role “Governor” for GlaxoSmithKline LLC, the Delaware limited liability company registered in Pennsylvania as a foreign LLC (filing number 0003913524). The dataset gives no appointment dates. The Department of State warns that the dataset contains businesses and records that are no longer current, so those entries are not presented here as current managers.
At group level, GSK plc’s 2025 Annual Report on Form 20-F identifies the following officers. Sir Jonathan Symonds has been Non-Executive Chair since 1 September 2019. Luke Miels has been Chief Executive Officer since 1 January 2026, succeeding Emma Walmsley. Julie Brown has been Chief Financial Officer since 1 May 2023. These officers belong to the UK parent company and are not officers of any US entity.
Recent officer changes
- 1 January 2026: Luke Miels succeeded Emma Walmsley as Chief Executive Officer of GSK plc (GSK plc 2025 Annual Report on Form 20-F).
Data availability
Availability: not applicable to the label. Pennsylvania’s open data gives roles and names for registered entities but no appointment or resignation dates and no nationality. GSK plc’s annual report publishes its board in full.
Sources
- Pennsylvania Department of State, Registered Businesses in PA (data.pa.gov dataset xvd7-5r2c): https://data.pa.gov/resource/xvd7-5r2c.json, rows updated 6 October 2026, retrieved 22 October 2026
- GSK plc, 2025 Annual Report on Form 20-F, filed 6 March 2026: https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm, retrieved 22 October 2026
Group Structure
Group structure of GlaxoSmithKline (H Q)
“GlaxoSmithKline (H Q)” is a location label for the GSK group’s US headquarters office at 2929 Walnut Street, Philadelphia. It is not an entity in the group’s legal structure, so it has no parent or subsidiaries of its own. The record does not identify which GSK legal person it refers to. The relationships below are verified group context, not links of this record.
GSK plc (England and Wales, 03888792) is the group’s ultimate parent. Its 2025 Annual Report on Form 20-F lists GlaxoSmithKline LLC, GlaxoSmithKline Holdings (Americas) Inc. and GlaxoSmithKline Capital Inc. among its wholly owned US subsidiaries, all held indirectly by GSK plc as at 31 December 2025. GLEIF records GSK plc as both the direct and the ultimate accounting consolidator of GlaxoSmithKline LLC, corroborated by accounts filings for 2025. That is a consolidation link, and it does not mean GSK plc holds the LLC directly.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| GSK plc | GB | 03888792 | Ultimate parent of the GSK group | Not applicable | Listed (LSE; NYSE ADS) | 31 December 2025 |
| GlaxoSmithKline LLC | US (Delaware; registered in Pennsylvania as a foreign LLC) | Delaware 4746253; Pennsylvania 0003913524 | Indirect subsidiary of GSK plc | 100% of LLC interests (indirect) | Active (GLEIF; Pennsylvania active-registrations data) | 31 December 2025 / 22 October 2026 |
| GlaxoSmithKline Capital Inc. | US (Delaware) | Delaware 2238362 (per GLEIF) | Indirect subsidiary of GSK plc; issuer of guaranteed notes | 100% (indirect) | Active (GLEIF) | 31 December 2025 |
Recent structural changes
- 27 October 2009: GLEIF gives this as the creation date of GlaxoSmithKline LLC, and Pennsylvania registered it as a foreign LLC on the same date. A Schedule 13D that GSK filed with the SEC on 10 December 2010 describes the LLC as formerly known as SmithKline Beecham Corporation.
- 18 July 2022: GSK plc separated its Consumer Healthcare business to form Haleon plc, an independent listed company (GSK plc 2025 Annual Report on Form 20-F).
Data availability
Availability: partial. The parent’s annual report lists every subsidiary with its effective percentage, but not the intermediate holding chain. GLEIF records accounting consolidation, not share ownership.
Sources
- GSK plc, 2025 Annual Report on Form 20-F, filed 6 March 2026: https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm, retrieved 22 October 2026
- GLEIF relationship records for LEI 549300Y2PZWSSLJYI255: https://api.gleif.org/api/v1/lei-records/549300Y2PZWSSLJYI255/ultimate-parent-relationship, retrieved 22 October 2026
- GLEIF LEI record 5493007Q8VD7Q3ZYZS59 (GlaxoSmithKline Capital Inc.): https://api.gleif.org/api/v1/lei-records/5493007Q8VD7Q3ZYZS59, retrieved 22 October 2026
- GSK plc, Schedule 13D on Anacor Pharmaceuticals, filed 10 December 2010: https://www.sec.gov/Archives/edgar/data/1411158/000095012310112757/c09546sc13d.htm, retrieved 22 October 2026
- Pennsylvania Department of State, Registered Businesses in PA (data.pa.gov dataset xvd7-5r2c): https://data.pa.gov/resource/xvd7-5r2c.json, retrieved 22 October 2026
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does GlaxoSmithKline (H Q) do?
GlaxoSmithKline (H Q) is not a registered company. It is a label for the GSK group's US headquarters office at 2929 Walnut Street, Philadelphia, and no Pennsylvania registration exists under that name (Pennsylvania Department of State open data, searched 22 October 2026). The group, headed by GSK plc (England and Wales, 03888792), develops and sells specialty medicines, vaccines and general medicines. One of its registered US entities, GlaxoSmithKline LLC, is a Delaware LLC (file 4746253) registered in Pennsylvania as a foreign LLC (0003913524).
Who owns GlaxoSmithKline (H Q)?
A location label has no shareholders. GSK plc's 2025 Annual Report on Form 20-F shows GlaxoSmithKline LLC as 100% held, indirectly, by GSK plc. The parent's notified major holders, as at 25 February 2026, are BlackRock, Inc. (5.69% of voting rights) and Dodge & Cox (5.04%), both held indirectly. Each percentage was calculated at the date it was notified.
Who is GlaxoSmithKline (H Q)'s UBO (Ultimate Beneficial Owner)?
No ultimate beneficial owner exists for a location label. None is identifiable for the group either: GSK plc is a widely held listed company whose only notified holdings are those of two asset managers, each just over 5% of voting rights. Any individual named as the UBO of this record would be unsupported.
Is GlaxoSmithKline (H Q) still an active company?
GlaxoSmithKline (H Q)'s status on Pennsylvania Department of State is listed as active.
What is GlaxoSmithKline (H Q)'s registered address?
The registered address on file for GlaxoSmithKline (H Q) is philadelphia, United States.
What is GlaxoSmithKline (H Q)'s revenue?
No revenue is reported for this label. As a group figure, GSK plc reported total turnover of £32,667 million and total operating profit of £7,932 million for the year ended 31 December 2025. These are consolidated group figures, not figures for any US entity (GSK plc 2025 Annual Report on Form 20-F and results release of 4 February 2026).
Is GlaxoSmithKline (H Q) listed on a stock exchange?
A location label cannot be listed. The group parent, GSK plc, has ordinary shares listed on the London Stock Exchange, and its American Depositary Shares, each representing two ordinary shares, trade on the New York Stock Exchange under the symbol GSK (GSK plc 2025 Annual Report on Form 20-F).
Who are the officers/directors of GlaxoSmithKline (H Q)?
The label has no officers of its own. At group level, GSK plc's 2025 Annual Report on Form 20-F names Sir Jonathan Symonds as Non-Executive Chair (since 1 September 2019), Luke Miels as Chief Executive Officer (since 1 January 2026, succeeding Emma Walmsley) and Julie Brown as Chief Financial Officer (since 1 May 2023).
Does GlaxoSmithKline (H Q) have a parent company or subsidiaries?
The label is not an entity in the group's legal structure. GSK plc (England and Wales, 03888792) is the group's ultimate parent. GlaxoSmithKline LLC, formerly SmithKline Beecham Corporation according to a 2010 SEC filing, is a wholly owned, indirectly held US subsidiary, and GLEIF records GSK plc as its direct and ultimate accounting consolidator.
Can Zavia monitor changes to GlaxoSmithKline (H Q)'s ownership over time?
This profile reflects a point-in-time snapshot from Pennsylvania Department of State. Zavia's monitoring API can track changes to GlaxoSmithKline (H Q)'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access GlaxoSmithKline (H Q)'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United States, so records like GlaxoSmithKline (H Q)'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Pennsylvania Department of State and was last synced on 29 September 2026.